Impact of a fixed combination of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% aqueous gel on health-related quality of life in moderate to severe acne vulgaris

Guy Webster, Diane M. Thiboutot, Diana M. Chen, Elizabeth Merikle

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The acne-specific quality of life (Acne-QoL) questionnaire was developed to measure the impact of facial acne across 4 domains (acne symptoms, role-emotional, self-perception, role-social) of health-related quality of life (HRQL). This analysis assessed the impact of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) gel on HRQL in a combined study population (N=2813) of participants with moderate to severe acne vulgaris. Although the results presented within do not include factors of study and study-by-treatment interaction, analyses were performed to confirm that the results were consistent across the 2 identical, double-blind, randomized studies and within each treatment group across studies to justify pooling the data from both studies. The Acne-QoL questionnaire was administered at baseline and at the end of treatment (week 12). Treatment with clindamycin-BPO 2.5% gel significantly improved participant-reported HRQL across all 4 domains compared with individual active ingredients and vehicle (P<.001). The percentage improvement in mean Acne-QoL domain scores with clindamycin-BPO 2.5% gel ranged from 37% to 59%. Because the negative impact of facial acne on HRQL is one of the primary motivators for patients to seek treatment, this analysis underscores the importance of physicians incorporating assessments of HRQL into their clinical decision making.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalCutis
Volume86
Issue number5
StatePublished - Nov 1 2010

Fingerprint

Acne Vulgaris
Gels
Quality of Life
Clindamycin
Benzoyl Peroxide
Therapeutics
clindamycin phosphate benzoyl peroxide combination
Double-Blind Method
Self Concept
Meta-Analysis
Physicians
Population

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{7ae341a7decd4a098c358c410d6371b4,
title = "Impact of a fixed combination of clindamycin phosphate 1.2{\%}-benzoyl peroxide 2.5{\%} aqueous gel on health-related quality of life in moderate to severe acne vulgaris",
abstract = "The acne-specific quality of life (Acne-QoL) questionnaire was developed to measure the impact of facial acne across 4 domains (acne symptoms, role-emotional, self-perception, role-social) of health-related quality of life (HRQL). This analysis assessed the impact of clindamycin phosphate 1.2{\%}-benzoyl peroxide 2.5{\%} (clindamycin-BPO 2.5{\%}) gel on HRQL in a combined study population (N=2813) of participants with moderate to severe acne vulgaris. Although the results presented within do not include factors of study and study-by-treatment interaction, analyses were performed to confirm that the results were consistent across the 2 identical, double-blind, randomized studies and within each treatment group across studies to justify pooling the data from both studies. The Acne-QoL questionnaire was administered at baseline and at the end of treatment (week 12). Treatment with clindamycin-BPO 2.5{\%} gel significantly improved participant-reported HRQL across all 4 domains compared with individual active ingredients and vehicle (P<.001). The percentage improvement in mean Acne-QoL domain scores with clindamycin-BPO 2.5{\%} gel ranged from 37{\%} to 59{\%}. Because the negative impact of facial acne on HRQL is one of the primary motivators for patients to seek treatment, this analysis underscores the importance of physicians incorporating assessments of HRQL into their clinical decision making.",
author = "Guy Webster and Thiboutot, {Diane M.} and Chen, {Diana M.} and Elizabeth Merikle",
year = "2010",
month = "11",
day = "1",
language = "English (US)",
volume = "86",
pages = "263--267",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "5",

}

Impact of a fixed combination of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% aqueous gel on health-related quality of life in moderate to severe acne vulgaris. / Webster, Guy; Thiboutot, Diane M.; Chen, Diana M.; Merikle, Elizabeth.

In: Cutis, Vol. 86, No. 5, 01.11.2010, p. 263-267.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of a fixed combination of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% aqueous gel on health-related quality of life in moderate to severe acne vulgaris

AU - Webster, Guy

AU - Thiboutot, Diane M.

AU - Chen, Diana M.

AU - Merikle, Elizabeth

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The acne-specific quality of life (Acne-QoL) questionnaire was developed to measure the impact of facial acne across 4 domains (acne symptoms, role-emotional, self-perception, role-social) of health-related quality of life (HRQL). This analysis assessed the impact of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) gel on HRQL in a combined study population (N=2813) of participants with moderate to severe acne vulgaris. Although the results presented within do not include factors of study and study-by-treatment interaction, analyses were performed to confirm that the results were consistent across the 2 identical, double-blind, randomized studies and within each treatment group across studies to justify pooling the data from both studies. The Acne-QoL questionnaire was administered at baseline and at the end of treatment (week 12). Treatment with clindamycin-BPO 2.5% gel significantly improved participant-reported HRQL across all 4 domains compared with individual active ingredients and vehicle (P<.001). The percentage improvement in mean Acne-QoL domain scores with clindamycin-BPO 2.5% gel ranged from 37% to 59%. Because the negative impact of facial acne on HRQL is one of the primary motivators for patients to seek treatment, this analysis underscores the importance of physicians incorporating assessments of HRQL into their clinical decision making.

AB - The acne-specific quality of life (Acne-QoL) questionnaire was developed to measure the impact of facial acne across 4 domains (acne symptoms, role-emotional, self-perception, role-social) of health-related quality of life (HRQL). This analysis assessed the impact of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) gel on HRQL in a combined study population (N=2813) of participants with moderate to severe acne vulgaris. Although the results presented within do not include factors of study and study-by-treatment interaction, analyses were performed to confirm that the results were consistent across the 2 identical, double-blind, randomized studies and within each treatment group across studies to justify pooling the data from both studies. The Acne-QoL questionnaire was administered at baseline and at the end of treatment (week 12). Treatment with clindamycin-BPO 2.5% gel significantly improved participant-reported HRQL across all 4 domains compared with individual active ingredients and vehicle (P<.001). The percentage improvement in mean Acne-QoL domain scores with clindamycin-BPO 2.5% gel ranged from 37% to 59%. Because the negative impact of facial acne on HRQL is one of the primary motivators for patients to seek treatment, this analysis underscores the importance of physicians incorporating assessments of HRQL into their clinical decision making.

UR - http://www.scopus.com/inward/record.url?scp=78650616028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650616028&partnerID=8YFLogxK

M3 - Article

C2 - 21214129

AN - SCOPUS:78650616028

VL - 86

SP - 263

EP - 267

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 5

ER -